A phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD) - 11/08/17
Doi : 10.1016/j.jaad.2017.04.099
Le texte complet de cet article est disponible en PDF.
Andreas Wollenberg, Ludwig Maximillian University; Michael D. Howell, MedImmune LLC; Emma Guttman-Yassky, Mount Sinai School of Medicine; Jonathan I. Silverberg, Northwestern University Feinberg School of Medicine; Claire Birrell, VHsquared Ltd; Chris Kell, MedImmune Ltd; Michelle Dawson, MedImmune Ltd; René van der Merwe, MedImmune Ltd
Le texte complet de cet article est disponible en PDF.| Commercial support: This study was funded by MedImmune/AstraZeneca. Medical writing and editorial support, including the printing and shipping of the poster was also funded by MedImmune. |
© 2017
Publié par Elsevier Masson SAS.
Vol 76 - N° 6S1
P. AB20 - juin 2017 Retour au numéro
Article précédent
- A phase 2a study to evaluate the safety, tolerability, and clinical effect of topically applied umeclidinium in subjects with primary axillary hyperhidrosis
- A phase 3 randomized, double-blind trial comparing the efficacy and safety of the fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064% (BD) aerosol foam with the aerosol foam vehicle used twice weekly as long-term maintenance
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?